2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1005

The Prevalence of Patellofemoral Osteoarthritis in China: A Multi-Center Population-Based Cross-Sectional Study
Abstract Number: 1970

The Prevalence of Rheumatoid Arthritis and Allergic Diseases and Their Association : A Study of the Korean National Health and Nutrition Examination Survey (KNHANES)
Abstract Number: 2523

The Prevalence, Incidence and Associated Factors for Liver Abnormalities in Psoriatic Arthritis: Resutls from a Longitudinal Observational Cohort
Abstract Number: 1432

The Prognostic Value of IgA Subtypes of Rheumatoid Factor and Anti-Citrullinated Protein Antibodies (ACPA) for Prediction of Therapeutic Responses to TNF Inhibitory Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 2239

The Recall Program: Data from a Multicenter Educational Event on Patients with Rheumatoid Arthritis
Abstract Number: 2949

The Relation of Cumulative Load to Prevalent Cartilage Damage in the Knee
Abstract Number: 2534

the Relationship between Biological Therapy, Work Productivity, and Activity Impairment in Patients with Psoriatic Arthritis: Prospective Multicentre Observational Study
Abstract Number: 2353

The Relationship between Disease Activity, VEGF and E-Selectin Levels with Arterial Stiffness in Rheumatic Patients Treated with Biological Agents
Abstract Number: 2195

The Relationship between Self-Reported Restless Sleep and Objectively Measured Physical Activity
Abstract Number: 1461

The Relationship between Serum IL-37 and Disease Activity in Patients with Rheumatoid Arthritis: Post-Hoc Analysis of Planetra Study
Abstract Number: 2843

The Relationship between Serum Urate Concentration and Incident Gout: An Individual Participant Data Analysis
Abstract Number: 2532

The Relationship between the Degree of Skin Involvement and Joint Activity in Patients with Psa: Experience from the Corrona Registry
Abstract Number: 2194

The Relationship between the Number of Prescription Medications and Physical Activity Amongst Patients with or at High Risk for Knee Osteoarthritis
Abstract Number: 2541

The Relationship between the Patient Acceptable Symptom State (PASS) and Disease Activity in Patients with Psoriatic Arthritis (PsA)
Abstract Number: 1352

The Relevance of Elevated CRP As an Inclusion Criterion in Clinical Trials in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].